Council for Responsible Nutrition
Home | Who is CRN? | About Dietary Supplements | Industry Regulation | Press Room | Annual Conference | Members Only

Legislation

DSHEA Summary and Analysis
Before and After DSHEA
Regulation
Food and Drug Administration (FDA)
Federal Trade Commission (FTC)
Self-Regulation
Regulations at a Glance
CRN Comments >
Federal Register Watch
International Policy
TransAtlantic Business Dialogue (TABD)
CODEX
CRN Comments to FDA back to index

The dietary supplement industry is regulated by the Food and Drug Administration and the Federal Trade Commission as well as by government agencies in each of the 50 states.

• CRN Comments to FDA on Docket No. 2006N-0168 Food Labeling: Revision of Reference Values and Mandatory Nutrients; Advance Notice of Proposed Rulemaking (PDF) 04.30.08
• CRN Comments to FDA on Docket No. FDA-2008-N-0077, Agency Information Collection Activities; Proposed Collection; Comment Request; MedWatch: The Food and Drug Administration Medical Products Reporting Program (PDF) 04.15.08
• CRN Comments to FDA on Docket No. Docket No. 2007D-0491, CFSAN 200755. Draft Guidance for Industry: Questions and Answers Regarding the Labeling of Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (PDF) 03.03.08

• CRN Comments to FDA on Docket No. 2007N-0464, Health Claims; Dietary Lipids and Cancer, Soy Protein and Coronary Heart Disease, Antioxidant Vitamins and Certain Cancers, and Selenium and Certain Cancers; Reevaluation; Opportunity for Public Comment FR Doc. E7-24813 (PDF) 02.19.08

• CRN Comments to FDA on Docket No. 2006N-0168, Food Labeling: Revision of Reference Values and Mandatory Nutrients; Advance Notice of Proposed Rulemaking (PDF) 12.20.07
• CRN Comments to FDA on GMP Interim Final Rule: Docket No. 2007N-0186, CFSAN 200736  Petition to Request an Exemption From 100 Percent Identity Testing of Dietary Ingredients: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements (PDF) 10.24.07
• CRN Comments to FDA on Draft Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims; Availability (PDF) 08.29.07
• CRN Comments to FDA on Program Priorities in the Center for Food Safety and Applied Nutrition, FY 2008 (PDF) 08.29.07

• CRN Comments to FDA on Draft Guidance for CAM, Docket # 2006D–0480 (PDF) 05.02.07

Position Statement: FDA Seeks Clarity on Complementary & Alternative Products: Misinterpretation of DRAFT GUIDANCE Causes Unwarranted Concerns; DSHEA is Safe (PDF)
• CRN Comments to FDA for Public Hearing on Functional Foods (PDF) 12.05.06
• CRN Comments to FDA's Center for Food Safety and Applied Nutrition (CFSAN) on FY 2007 Program Priorities Docket # 1998N-0359 (formerly 98N-0359) (PDF) 08.09.06
• CRN Comments to FDA Docket # 2005P-0305 and Comment requested on Pyridoxamine—Citizen Petition (PDF) 03.07.06
• CRN Comments to FDA Docket # 2005P-0305 and Comment requested on Pyridoxamine—Citizen Petition (PDF) 12.16.05
• Joint letter from CRN, AHPA and NNFA to FDA on the Utah ephedra ruling (PDF) 05.17.05

• CRN Comments to FDA Docket # 2004N-0454: Premarket Notification for New Dietary Ingredients (PDF) 02.01.05
• CRN Comments to FDA Docket # 2004D-0466: Substantiation for Dietary Supplement Claims (Statements of Nutritional Support, Structure/Function Claims) (PDF) 01.11.05
• CRN Comments to FDA Docket # 2004N-0454: On Six Major Topics Outlined by FDA on New Dietary Ingredients (PDF) 11.15.04
• CRN President Annette Dickinson's Presentation from the FDA public meeting on New Dietary Ingredients (PPT) 11.15.04
• Peter Barton Hutt (CRN Counsel, Covington & Burling) Comments to FDA Docket # 2004N-0454: On Six Major Topics Outlined by FDA on New Dietary Ingredients (PDF) 11.15.04
• CRN Comments to FDA Docket # 2003N-0496 Food Labeling: Health Claims and Dietary Guidance (PDF) 02.25.04
• Joint Comments to FDA Docket # 96N-0417 on GMPs (CRN, AHPA and NNFA) 01.30.04

• CRN Comments to FDA Docket # 96N-0417 on GMPs 08.11.03
 + CRN Comments on Economic Impact of GMPS submitted 9.10.03
• CRN Comments to FDA on GMPs with 4-way Comparison (PDF) 07.08.03
• CRN Comments to FDA on Recordkeeping Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (PDF) 07.08.03
• CRN Comments to FDA on Administrative Detention Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (PDF) 07.08.03

• CRN Comments to FDA on Consumer Health Information for Better Nutrition (PDF) 05.27.03

• CRN/CHPA Comments to FDA on Consumer Health Information for Better Nutrition (PDF) 05.27.03

• CRN Letter to FDA and FTA on Coral Calcium (PDF) 05.15.03
• CRN Comments to FDA on Registration of Food Facilities Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 04.04.03
• CRN Comments to FDA on Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 04.04.03
• CRN Comments to FDA on Ephedra 04.03.03
• CRN Comments to FDA on First Amendment/Health Claims 10.30.02 (PDF)
• CRN Comments to FDA on the Implementation of the Bioterrorism Act of 2002 08.30.02
• CRN Comments to FDA on CFSAN Priorities for 2003 08.20.02 (PDF)
• CRN Comments to FDA on Ephedra 12.20.00
1828 L Street, NW, Suite 510 • Washington, DC, 20036-5114 • (202) 204-7700 fax (202) 204-7701 • e-mail webmaster@crnusa.org